Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation by Wong, Banny S et al.
© 2010 Wong et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical and Experimental Gastroenterology 2010:3 49–56
Clinical and Experimental Gastroenterology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
49
REviEW
open access to scientific and medical research
Open Access Full Text Article
8091
Role of prucalopride, a serotonin (5-HT4) 
receptor agonist, for the treatment of chronic 
constipation
Banny S Wong 
Noriaki Manabe 
Michael Camilleri
Clinical Enteric Neuroscience 
Translational and Epidemiological 
Research (C.E.N.T.E.R.), Mayo Clinic, 
Rochester, Minnesota, USA
Correspondence: Michael Camilleri
Mayo Clinic, Charlton 8-110, 200 First St 
SW, Rochester, MN 55905, USA
Tel +1 507 266 2305
Email camilleri.michael@mayo.edu
Abstract: Constipation affects up to a quarter of the population in developed countries and is 
associated with poor quality of life and significant economic burden. Many patients with chronic 
constipation are dissatisfied with current therapy due to lack of long-term efficacy or side effects. 
Previous nonselective 5-hydroxytryptamine receptor 4 (5-HT4) agonists have been associated with 
significant interactions with other receptors (5-HT1B, 5-HT1D, and 5-HT2B for tegaserod; hERG for 
cisapride), leading to adverse cardiovascular events resulting in withdrawal of these drugs from the 
market. Prucalopride is a novel gastrointestinal prokinetic agent. It acts as a high affinity, highly-
selective 5-HT4 agonist. Its efficacy in patients with chronic constipation has been demonstrated 
in several phase II and phase III clinical trials showing significant improvements in bowel transit, 
bowel function, gastrointestinal symptoms, and quality of life, with benefit maintained for up to 
24 months in open label, multicenter, follow-up studies. Prucalopride’s high selectivity for the 5-HT4 
receptor may explain its favorable safety and tolerability profiles, even in elderly subjects with stable 
cardiovascular disease. Prucalopride is a well tolerated and efficacious prokinetic medication that 
should enhance the treatment of chronic constipation unresponsive to first-line treatments.
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Introduction
Constipation is a common, often chronic, gastrointestinal disorder with higher preva-
lence in women and the elderly.1 The Rome III Committee on Functional GI Disorders2 
set criteria for the diagnosis of chronic constipation which include a description of 
chronicity (for the last 3 months with symptoms and an onset at least 6 months prior) 
and symptoms (2 or more of which must be present at least 25% of defecations). These 
symptoms include: fewer than 3 bowel movements per week, hard or lumpy stools, 
straining with defecation, a sensation of incomplete evacuation, a sensation of anorectal 
obstruction or blockage, and use of maneuvers to assist defecation.2 It affects 10% to 
15% of the population in developed countries,3,4 and up to 27% of North Americans.5 
In a survey of almost 14,000 persons, of whom 12% reported constipation, over half 
experienced symptoms for three or more years.4 In the United States (US), constipation 
results in 92,000 hospitalizations and more than 2.5 million physician visits per year; 
these figures may be rising with time.1,6
Chronic constipation compromises health-related quality of life (HR-QOL) pro-
portionately to symptom severity.3,7,8 It is also associated with significant economic 
impact, directly from medical evaluation and treatment including the problem of self 
medication and adherence to therapy, as well as indirectly from absenteeism. Thus, 
chronic constipation is a significant public health problem.3,9Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Constipation can be classified by three major categories 
based on pathophysiology: normal transit constipation, slow 
transit constipation, and defecatory disorder.10
Overview of standard therapies, 
development of new agents
Treatment for constipation is often guided by the severity 
of symptoms and the underlying pathophysiology. Lifestyle 
changes such as increasing oral fluid intake and regular 
exercise do not appear efficacious in alleviating chronic 
constipation, except in cases of dehydration.11,12 Other thera-
peutic approaches for chronic constipation include fiber intake 
(20 to 25 g daily via diet or with fiber supplements), osmotic 
laxatives (such as polyethylene glycol, milk of magnesia, 
lactulose, or sorbitol), stimulant laxatives (such as bisacodyl or 
senna derivatives), secretory agents (such as lubiprostone),13,14 
and prokinetic drugs (such as cisapride and tegaserod, which 
are no longer easily available in most countries).
The nonselective 5-hydroxytryptamine receptor 4 (5-HT4) 
receptor agonists, cisapride and tegaserod, promote intestinal 
motility and relieve constipation,15–17 but their lack of selec-
tivity for the 5-HT4 receptor may account for adverse car-
diovascular events, resulting in their restricted   availability.18 
Tegaserod is an agonist at 5-HT1B and 5-HT1D receptors and 
an antagonist at 5-HT2B receptors within the range of concen-
trations used for treatment of constipation. These nonselec-
tive interactions may explain the association of tegaserod 
with rare instances of ischemic adverse events, including 
stroke and angina.18 Cisapride inhibits the human ether-à-
go-go related gene (hERG) potassium channel at therapeutic 
concentrations. This can lead to cardiac electrophysiologic 
derangements including QT prolongation, torsade de pointes, 
ventricular tachycardia, and ventricular fibrillation, particu-
larly in patients with underlying cardiovascular diseases or 
the concurrent use of a medication that inhibits metabolism 
of cisapride.18,19
Biofeedback retraining is essential for outlet dysfunction 
resulting in chronic constipation. Intractable cases of severe 
slow transit constipation associated with colonic inertia may 
require colectomy with ileorectostomy.10
Despite their widespread use, evidence of long-term 
clinical efficacy for laxative medications is lacking.20–22 
Patient dissatisfaction with current laxative treatment is high, 
with lack of efficacy reported by 82% and concerns about 
side effects in 16% of constipated subjects in a US based 
survey.8
New pharmacotherapeutic approaches for treatment of 
chronic constipation include guanylate cyclase C agonists 
(eg, linaclotide),23,24 neurotrophins (eg, NT-3),25,26 and 
  serotonergic agents, predominantly 5-HT4 receptor agonists, 
with enterokinetic properties. This class of compounds 
includes prucalopride, velusetrag, and ATI-7505. Of these, 
the agent with the largest clinical trial evidence of efficacy 
is prucalopride.
Pharmacology and mode of action 
of prucalopride
Prucalopride (previously known as R093877 and R108512) 
is a dihydro-benzofurancarboxamide derivative, with a 
different structure relative to older serotonergic gastroin-
testinal prokinetics such as cisapride (a substituted benz-
amide derivative) and tegaserod (an aminoguanidine indole 
derivative). Prucalopride is a highly selective agonist and 
has high affinity for 5-HT4 receptors promoting cholinergic 
and nonadrenergic, noncholinergic neurotransmission by 
enteric neurons. Prucalopride displays high affinity binding 
to human 5-HT4a and 5-HT4b receptor isoforms with pKi val-
ues of 8.6 and 8.1, respectively.27 Prucalopride also displays 
very high specificity for the 5-HT4 receptor isoforms, with a 
greater than 290-fold selectivity for 5-HT4 receptor isoforms 
than for the only three other receptors showing measurable 
affinity to prucalopride (human dopamine D4 receptor with 
pKi of 5.63, mouse 5-HT3 receptor with pKi of 5.41, and 
human σ1 receptor with pKi of 5.43).27 Agonist binding to the 
G protein-coupled 5-HT4 receptor activates adenylate cyclase 
and increases intracellular cyclic adenosine monophosphate 
(AMP) levels.28
Specific activation of the 5-HT4 receptors that are present 
in the range quantities in the gastrointestinal tract promotes 
gastrointestinal motility and mucosal secretion.28 Gastroin-
testinal motility stimulation has been demonstrated in several 
experimental models in vitro and in vivo. In isolated guinea 
pig colon, prucalopride induced dose-dependent, nonadren-
ergic, noncholinergic contractions (pEC50 = 7.48 ± 0.06).27 
Selectivity for the 5-HT4 receptor was confirmed via inhibi-
tion by a selective 5-HT4 antagonist (GR113808), but lack 
of inhibition by 5-HT2A (ketanserin) and 5-HT3 antagonists 
(granisetron).27 Prucalopride also stimulated contractions in 
the stomach (in rat and dog) and colon (in dog and human) 
(pEC50 = 7.50 ± 0.08), but mediated relaxation of the esopha-
gus (in rat) (pEC50 = 7.81 ± 0.17) in a manner sensitive to 
5-HT4 receptor antagonism.27
Prucalopride stimulated contractions in colonic longitudinal 
smooth muscles by promoting acetylcholine release via acti-
vation of 5-HT4 receptors on presynaptic, cholinergic enteric 
neurons.29 Prucalopride also induced relaxation of human Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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colonic and canine rectal circular smooth muscles through 
local 5-HT4 receptor activation.29,30 Therefore, 5-HT4 agonists 
facilitate gastrointestinal motility by promoting longitudinal 
smooth muscle contractility while suppressing the resistance 
to propulsion due to circular smooth muscle contraction.
Prucalopride’s in vivo effects in the canine colon suggest a 
coordinated, region-specific mechanism, whereby longitudinal 
smooth muscles demonstrate increased contractile activity 
in the proximal colon, but reduced contractility in the distal 
colon.31 In addition, circular smooth muscle relaxation is 
negligible in the proximal colon, but increasingly more pro-
nounced towards the distal colon with prucalopride treatment.30 
In conscious, fasted dogs, prucalopride also induces colonic 
giant migrating contractions (GMC) that propagate along the 
entire length of the colon to facilitate propulsion of luminal 
contents.31 GMC are the canine equivalent to human high 
amplitude propagated contractions (HAPC). A reduction of 
HAPC is observed in patients with idiopathic constipation.32
Prucalopride, given intravenously at a dosage of 1 to 
2 mg/kg in fasted rats, increased whole gut transit of activated 
charcoal, mainly by increasing colonic transit, and without 
affecting gastric or proximal small bowel transit.33 On the 
other hand, in dogs, prucalopride dose-dependently promotes 
gastric contractility34 and accelerates gastric emptying.35
Pharmacokinetics of prucalopride
Prucalopride is rapidly and extensively absorbed from the 
gastrointestinal tract after oral dosing. Peak plasma con-
centration of 4.34 ng/mL (mean) was achieved in 2.1 hours 
after a single 2 mg dose in 14 healthy adult subjects.36 
Absolute oral bioavailability of prucalopride exceeds 93% 
and is not affected by food intake.36 Prucalopride displays 
linear pharmacokinetics with exposure to drug, increasing 
proportionally with increasing dosage over the dose range 
1 to 20 mg daily.36 Plasma protein binding is low at 28% to 
33%.36 Extensive distribution is reflected in a steady state 
volume of distribution of 567 L.36
Prucalopride undergoes limited metabolism in the human 
body. Only small amounts of its metabolites are found in 
the urine and feces, with the major metabolite accounting 
for less than 4% of the dose.37 Unchanged prucalopride 
accounts for about 85% of the plasma radioactivity after 
administration of radiolabeled drug in an oral dose study.37 
The drug is excreted largely unchanged, with about 60% of 
the administered dose excreted in urine by active secretion 
and passive filtration and greater than 6% appearing in the 
feces.36 The elimination half-life of prucalopride of between 
24 and 30 hours supports once daily dosing.37
Age, gender, body weight, and race have no influence on 
pharmacokinetics. Plasma prucalopride concentrations are 
nearly 30% higher in the elderly due to age-related decline in 
renal function. Therefore, a reduction of the dosage to half the 
normal adult dosage is recommended for elderly patients and 
for patients with severe renal insufficiency (creatinine clear-
ance less than 25 mL/min).37 Given the relatively low level 
of metabolism by the liver, hepatic impairment is unlikely 
to alter prucalopride pharmacokinetics significantly. Halving 
the normal adult dosage is recommended for patients with 
severe liver dysfunction.37
Prucalopride has a low potential for drug-drug interac-
tions due to lack of significant metabolism by the cytochrome 
P450 system at therapeutic concentrations and due to lack of 
extensive binding to plasma protein.
Efficacy studies
Pharmacodynamics in humans
In healthy volunteers, placebo-controlled pharmacodynamic 
studies showed that prucalopride treatment for 1 week 
accelerated colonic transit at 0.5, 1, 2, and 4 mg/day,38,39 
orocecal transit at 1 mg/day,40 and whole gut transit at 1 and 
2 mg/day.40 An increase in stool frequency and a loosening 
of stool consistency were also documented.38–41 There was 
no rebound effect on bowel function after discontinuation of 
drug.40 Prucalopride’s effects on gastrointestinal transit and 
bowel function in healthy men were comparable to those 
observed in healthy women in a trial that enrolled an equal 
number of male and female healthy volunteers.39 In addition, 
a study conducted exclusively in males provided results 
similar to those of trials that enrolled mostly females.40
In patients with chronic constipation in whom an evacua-
tion disorder was excluded (Figure 1), prucalopride therapy at 
4 mg/day for 1 week42 or at 1 mg/day for 4 weeks43 acceler-
ated gastric emptying half-time,42 ascending colon emptying 
half-time,42 overall colonic transit,42 orocecal transit time,42,43 
and whole gut transit.43 Prucalopride-induced acceleration 
of colonic transit was also associated with increased stool 
frequency and loosening of stool consistency in patients 
with chronic constipation.43,45 Prucalopride exhibited dose 
responsiveness in effects on gastrointestinal transit and 
bowel functions.43,44
Therapeutic efficacy
Phase iiB studies
Phase IIB clinical trials assessing prucalopride’s efficacy 
in chronic constipation were conducted for up to 4 weeks 
with dosage ranging from 0.5 to 4 mg/day.45–48 The primary Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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endpoint of $3 spontaneous, complete bowel movements per 
week (SCBM/w) is thought to reflect clinical response, since 
consensus criteria show that healthy people have 3 bowel 
movements per week. This endpoint was achieved in ∼32% and 
55% for patients on 2 mg/day and 4 mg/day, respectively.46,47 
Another endpoint of significant clinical relevance to patients 
is the ability to have spontaneous bowel movements (SBM). 
SBM per week (SBM/w) were increased 1.8- to 3.5-fold 
with prucalopride relative to placebo.44,45,49 Prucalopride also 
ameliorated a number of secondary endpoints: frequency of 
straining during bowel movements, stool consistency, subjec-
tive sense of constipation, and time to first bowel movement.49 
In children aged 4 to 12 years, prucalopride decreased number 
of days with hard stools or without stools and increased aver-
age number of days with bowel movements.50
Studies conducted in subgroups of patients with   secondary 
constipation suggest prucalopride is also efficacious:
a.  In opioid-induced constipation, ∼36% of prucalopride-
treated patients had an increase of one or more SMB/w, 
compared to 23% for patients on placebo.51
b.  In patients with spinal cord injury, prucalopride 
(2 mg/day) increased number of bowel movements per 
week (BM/w) and reduced colonic transit relative to 
placebo without affecting stool consistency.52
c.  In patients with multiple sclerosis and constipation, 
prucalopride (1 to 2 mg/day) decreased time to first BM and 
severity of constipation, and increased number of BM/w 
by $1 in 57% of patients on prucalopride compared to 25% 
placebo. This led to a decrease in the need for laxatives.53
Phase iii studies
The clinical efficacy of prucalopride is best demonstrated 
by the three pivotal phase III clinical trials conducted in the 
treatment of chronic constipation in patients not experiencing 
symptomatic relief with laxatives (Table 1).54–56 The trials 
had virtually identical design (2-week run-in, 12 weeks on 
treatment), doses (placebo, prucalopride 2 and 4 mg) and 
primary outcome measurements (percentage of patients 
achieving $3 SCBM/w over the 12-week treatment period) 
in patients with chronic constipation (based on self report 
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Figure 1 Effect of prucalopride on small bowel and colonic transit.
Notes: Right panel: Two sets of scintigraphic images obtained from 2 study objects: A) one receiving placebo and B) the other 4 mg of prucalopride. Top images are 4-hour scans 
and bottom images are 24-hour scans for each individual. Prucalopride accelerates movement of the radioisotope through the colon both at 4 and 24 hours in comparison with 
placebo. A higher GC value implies more rapid colonic transit, with a value of 4.1 implying that most of the isotope has already been excreted. Left panel: Summary data from 
groups of patients treated with placebo or prucalopride 2 or 4 mg/day. The histograms show the acceleration of small bowel and ascending colon transit.
*P  0.05 vs placebo treatment.. 
Reprinted from Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates Gi and colonic transit in patients with constipation without a rectal evacuation disorder. 
Gastroenterology. 2001;120:354–360.76
Abbreviations: GC, geometric center at 4 (GC 4 h) and 24 (GC 24 h) hours; SBTT, small bowel transit time; AC, ascending colon; pru, prucalopride.Clinical and Experimental Gastroenterology 2010:3
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of 2 SCBM/w for 6 or more months,54 averaged over 
12 weeks,55 and for a minimum of 2 weeks,56 respectively). 
Patients were required to have hard or lumpy stool, as well 
as straining on defecation and a sensation of incomplete 
evacuation during $25% of BM. Secondary constipation 
was excluded.
Efficacy endpoints were derived from daily diaries of 
bowel habits, the Patient Assessment of Constipation Symp-
toms (PAC-SYM),57 and the Patient Assessment of Constipa-
tion Quality of Life (PAC-QOL).58 Compared to 11% of the 
placebo group, 23.6% (2 mg/day) and 24.7% (4 mg/day) of 
patients achieved the primary endpoint ($3 SCBM/w), which 
reflects normalization of bowel function.54
Prucalopride was also effective in significantly improving 
secondary endpoints, such as proportion of patients achieving 
an increase of $1 SCBM/w over the 12 weeks of therapy 
relative to baseline, the average number of SCBM/w, stool 
consistency, time to first SCBM, sensation of incomplete 
evacuation, need for rescue medication, patient-rated 
satisfaction, overall PAC-SYM score, and overall treatment 
effectiveness.54–56
Efficacy of prucalopride in retreatment was shown during 
a second 4-week treatment period compared to the first 4-week 
period: retreatment was associated with improved bowel 
function and associated patient-reported symptoms.59
There are no reported direct comparative studies of pru-
calopride with other colonic prokinetics or secretagogues. 
The data from clinical trials regarding the average increase 
in number of BM/w with prucalopride suggest that it may be 
more efficacious (+1.4–1.8 SCBM/w)54 relative to the mean 
number of BM/w on placebo when compared to tegaserod 
(+1.3 BM/w) and renzapride (+0.2 BM/d), and similar to 
the efficacy of cisapride (+1.9 SBM/w) and bulk laxatives 
(+1–2 BM/w).60–63
In open label, long-term, follow-up studies, continuation 
of prucalopride for a median of about 1 year and a range of 
up to 24 months was associated with sustained patient sat-
isfaction with bowel function which was documented every 
3 months for up to 18 or 24 months.64,65 There was also overall 
satisfaction with treatment.
Safety and tolerability
Prucalopride’s high selectivity at therapeutic dosages 
minimizes interactions with other receptors that may lead to 
serious adverse events.18 It is eliminated from the human body 
without extensive metabolism, thus reducing potential for 
drug–drug interactions with medications that affect hepatic 
or renal metabolism and clearance.36Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Cardiac safety
Since the report of 341 cases of cisapride-related, serious 
cardiac arrhythmias in 2000,66 extensive cardiac monitor-
ing, in particular the duration of the QTc interval, has been 
mandated for development of 5-HT4 receptor agonists, as 
there are 5-HT4 receptors in the atrium and ventricle. Pru-
calopride has some inotropic and chronotropic effects on the 
heart;67–69 however, studies with prucalopride in the porcine 
atrium suggest low cardiac risks,70 consistent with the almost 
300-fold difference in affinity constant for the 5-HT4 receptor 
and hERG.18 This indicates a high safety margin and low risk 
of cardiac side effects with prucalopride.71,72 No arrhythmic 
activity was demonstrated in human atrial cells treated with 
prucalopride, even after pretreatment with β-adrenoceptor 
antagonists to increase the proarrhythmic potential.73
In the prucalopride clinical trial cohorts (∼4000 people), 
there were no clinically relevant cardiac adverse events. In 
healthy volunteers in two phase I trials exposing healthy 
volunteers to up to 10 times the therapeutic dosage of pruca-
lopride, there was higher heart rate and associated decreases 
in PQ and QT intervals, but not in the Fridericia-corrected 
QT (QTcF) interval.74 Longer-term clinical trials exposing 
patients to up to 4 mg/day for a maximum of 24 months 
confirmed prucalopride’s safety.64 A phase II safety study 
in nursing home patients, of whom .85% had a history of 
cardiovascular disease,75 showed no detrimental change in 
pulse rate, blood pressure, electrocardiographic indices, or 
laboratory safety parameters.75
General tolerability
Prucalopride is generally well tolerated; the adverse event 
profile after long-term treatment is similar to that of 12-week 
exposure. The most common adverse events (which occur 
in 10% or more of treated subjects) are headache, nausea, 
abdominal pain, and diarrhea.45,49,54–56,76,77 Most adverse events 
have been mild or of moderate severity, transient, and have 
occurred mainly on the first day of treatment, independent 
of the dosage received. Treatment-related adverse events 
leading to discontinuation of medication occurred in 8.3% 
of patients.54–57 Four patient deaths have been reported, with 
three unrelated to drug and treatment information unavailable 
for the fourth patient.54,65
Patient perspectives: quality  
of life, satisfaction, acceptability,  
and adherence
As illustrated above, prucalopride treatment was associated 
with improved quality of life (based on PAC-QOL) during 
placebo-controlled trials and satisfaction with bowel function 
was maintained during open label treatment with prucalopride 
for up to 24 months (less than 10% prucalopride cessation 
because of treatment emergent adverse events). Therefore, 
patients appear to tolerate and benefit from this treatment in 
the medium- and long-term. It is also worth noting that .80% 
patients entering the pivotal trials of 12 weeks’ duration 
reported lack of satisfaction with current laxatives and there 
was significant improvement in QOL scores as estimated by 
the validated PAC-QOL assessment.
Conclusion
Prucalopride is a novel compound, stimulating 5-HT4 
receptors with high affinity. The lack of interaction of pru-
calopride with other receptors or channels at therapeutic 
doses is advantageous relative to available prokinetics. 
In patients with chronic constipation, prucalopride increases 
stool frequency and loosens stool consistency by stimulating 
gastrointestinal and colonic motility. The drug appears to 
be safe (with a safety window of ∼300 between efficacy in 
constipation and proarrhythmic potential), is well tolerated, 
and adverse events are mild.
In July 2009, prucalopride was approved by the European 
Medicines Agency for the symptomatic treatment of chronic 
constipation for women in whom laxatives fail to provide 
satisfactory relief.78 Prucalopride will be the first oral 
medication marketed for severe chronic constipation in the 
European Union. Recommended dosage is 2 mg by mouth 
once daily, except for those over 65 years of age for whom 
the recommended dosage is 1 mg by mouth once daily. 
The dose can be subsequently increased to 2 mg daily, as 
tolerated.
Current data suggest that, at the least, prucalopride will 
prove to be a valuable addition to the therapeutic arsenal in 
treating chronic constipation. At present, prucalopride should 
be regarded as a second-line treatment after supplementation 
of fiber, and osmotic, or over-the-counter laxatives.
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